Sales of flagship drug Revlimid drive Celgene profit; forecast raised

NEW YORK (Reuters) – Celgene Corp raised its 2016 profit forecast and exceeded expectations for second-quarter earnings on Thursday on the strength of its flagship multiple myeloma drug Revlimid and growth in newer medicines, sparking a 2 percent jump in its shares.

Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *